Research programme: nanomedicines - Pfizer/Merck & Co

Drug Profile

Research programme: nanomedicines - Pfizer/Merck & Co

Alternative Names: KSP Accurin™ - Pfizer/Merck & Co; KSP inhibitors - Pfizer/Merck & Co; PLK1 Accurin™ - Pfizer/Merck & Co; PLK1 inhibitors - Pfizer/Merck & Co

Latest Information Update: 25 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BIND Therapeutics; Merck & Co
  • Developer Merck & Co; Pfizer
  • Class
  • Mechanism of Action KIF11 protein inhibitors; Polo-like kinase 1 inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 May 2016 BIND Therapeutics files for Chapter 11 bankruptcy
  • 06 Nov 2014 BIND Therapeutics and Merck & Co sign an agreement for the development of nanomedicines for cancer
  • 06 Nov 2014 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top